Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
Michael J. Pontecorvo(Eli Lilly (United States)), Michael Grundman(University of San Diego), Cyril Sadowsky(Nova Southeastern University), Amit D. Joshi(Harvard University), Daniel Skovronsky(Eli Lilly (United States)), Eric M. Reiman(Alzheimer's Association), Adam Fleisher(Banner Alzheimer’s Institute), Mark A. Mintun(Washington University in St. Louis), Terence Z. Wong(Harvard University), Ming‐Chi Lu(University of California, San Francisco), Keith A. Johnson(Brigham and Women's Hospital), Marwan N. Sabbagh(Cleveland Clinic), Alan Carpenter, Reisa A. Sperling(Harvard University), P. Murali Doraiswamy(Alzheimer’s Disease Neuroimaging Initiative)
Cited by 196
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k